The PNPLA3-I148M Variant Confers an Antiatherogenic Lipid Profile in Insulin-resistant Patients.

doi:10.1210/clinem/dgaa729

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

The PNPLA3-I148M Variant Confers an Antiatherogenic Lipid Profile in Insulin-resistant Patients.

The Journal of clinical endocrinology and metabolism - 1 Jan 2021

Luukkonen Panu K, Qadri Sami, Lehtimäki Tiina E, Juuti Anne, Sammalkorpi Henna, Penttilä Anne K, Hakkarainen Antti, Orho-Melander Marju, Arola Johanna, Yki-Järvinen Hannele

Abstract excerpt

CONTEXT: The I148M (rs738409-G) variant in PNPLA3 increases liver fat content but may be protective against cardiovascular disease. Insulin resistance (IR) amplifies the effect of PNPLA3-I148M on liver fat. OBJECTIVE: To study whether PNPLA3-I148M confers an antihyperlipidemic effect in insulin-resistant patients. DESIGN: Cross-sectional study comparing the impact of PNPLA3-I148M on plasma lipids and lipoproteins...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Atherosclerosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Finland

Share to Isoleucine

Share to Lipase

Share to Lipid Metabolism

Share to Lipidomics

Share to Lipoproteins

Share to Methionine

Source

Open in PubMed

Identifiers

PMID: 33064150
DOI: 10.1210/clinem/dgaa729

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The PNPLA3-I148M Variant Confers an Antiatherogenic Lipid Profile in Insulin-resistant Patients.PMID 33064150Read ↗

Insulin resistance is an integral feature of MASLD even in the presence of PNPLA3 variantsSemantic proximity Read ↗

The PNPLA3 I148M polymorphism is associated with insulin resistance and nonalcoholic fatty liver disease in a normoglycaemic population.Semantic proximity Read ↗

Function of PNPLA3 I148M-Lessons From In Vivo Studies in Humans.Semantic proximity Read ↗

I148M variant in PNPLA3 reduces central adiposity and metabolic disease risks while increasing nonalcoholic fatty liver disease.Semantic proximity Read ↗

PNPLA3 rs738409 underlies treatment response in nonalcoholic fatty liver diseaseSemantic proximity Read ↗

PNPLA3 I148M Polymorphism in Patients with Nonalcoholic Fatty Liver Disease, Obesity and Prediabetes.Semantic proximity Read ↗

PNPLA3 I148M Interacts With Environmental Triggers to Cause Human Disease.Semantic proximity Read ↗

The I148M PNPLA3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls.Semantic proximity Read ↗

PNPLA3 I148M is involved in the variability in anti-NAFLD response to exenatide.Semantic proximity Read ↗

Morbid obesity exposes the association between PNPLA3 I148M (rs738409) and indices of hepatic injury in individuals of European descent.Semantic proximity Read ↗

Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene.Semantic proximity Read ↗

Circulating triacylglycerol signatures in nonalcoholic fatty liver disease associated with the I148M variant in PNPLA3 and with obesity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.